PubLedge

Operational observation (not an issued term)

OAIP's Authorized AI Pilots page, retrieved 2026-10-15 (UTC), still lists Doctronic as Active with the initial term October 24, 2025 – October 24, 2026. It reports Phase 1, requiring licensed-practitioner authorization of every request, and says Phase 2 requires approval by medication group and has not been approved. This is a dated agency status observation, not independently established operation, compliance, an amended term, or permission to continue past October 24. No amendment document, written Proposal approval, Phase 2 approval, or extension decision was located among the links on the register, Doctronic pilot page, and FAQ reviewed in this source check; their absence from those pages does not establish that no such document exists.

The agreement PDF linked by the reviewed pilot page was retrieved 2026-10-15 (UTC) and is byte-identical to the signed source retained September 9. It still describes the first 250 patients as Phase One and includes Butalbital and Flecainide in Schedule C. The current register and FAQ continue to describe a per-medication-group threshold and removal of those medications. The source conflict remains unresolved: the approval mechanism, document, date, signatories or approving official, and exact changed text are unverified. The FAQ now describes a general program allowance of up to two extensions, while Section 13 of this agreement permits a single extension request; the FAQ is not an amendment or a decision extending this agreement. Renewal beyond the recorded initial term, termination, and compliance remain unverified. This source check does not renew the September 23 legal verification date.

OAIP's May 19, 2026 outcomes report describes January-April activity while the pilot was still in Phase One. It says the AI recommended renewal in 72% of cases, and each recommendation then went to human physician review. Within that 72% subset, the first reviewing physician agreed renewal was appropriate in 91% of cases. When the first physician requested more information, a second physician also reviewed the case; OAIP reports that either the first or second physician found renewal appropriate in 97% of that recommendation subset based on the information the AI gathered. In the remaining 28% of all cases, the AI escalated without recommending renewal; physicians agreed the escalation was appropriate in 69% of that escalation subset.

The report says the sample was limited, based on reports from Doctronic physicians, and subject to a separate OAIP review. It is an operational observation, not an amendment or issued term. It does not establish a later phase, compliance, extension, termination, or the pilot's current phase or status after the reporting period.

OAIP's AI FAQ, observed September 9, 2026, says the Phase 2 transition criteria were updated from 250 prescriptions total to 250 medications in each medication group, still subject to OAIP approval, and that Butalbital and Flecainide were removed from the formulary. The retained signed agreement instead describes the first 250 patients as Phase One and includes both medications in its formulary. OAIP's current Doctronic page links the signed agreement, outcomes report, medical-board correspondence, and a policy memorandum, but no signed amendment. The FAQ is therefore retained as an official dated observation and explicit source conflict; it does not establish the amendment mechanism or effective date, OAIP approval to enter Phase Two, or the pilot's current phase.

OAIP's Authorized AI Pilots page, retrieved 2026-09-24 (UTC), lists Doctronic as Active with term October 24, 2025 – October 24, 2026. It states that the pilot is still in Phase 1, that moving to Phase 2 requires OAIP approval by medication group, and that Phase 2 has not been approved. The same page refers to "the 2026 amendment" as tightening that threshold and removing two medications, but neither it nor the Doctronic pilot page links an amendment document. The amendment's date, signatories, and exact text remain unverified; the retained signed agreement is the only executed text reviewed.